As of 2025-06-02, the Intrinsic Value of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd (600613.SS) is 4.28 CNY. This 600613.SS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 6.48 CNY, the upside of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd is -34.00%.
The range of the Intrinsic Value is 3.48 - 5.87 CNY
Based on its market price of 6.48 CNY and our intrinsic valuation, Shanghai Shenqi Pharmaceutical Investment Management Co Ltd (600613.SS) is overvalued by 34.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 3.48 - 5.87 | 4.28 | -34.0% |
| DCF (Growth 10y) | 4.13 - 6.86 | 5.04 | -22.2% |
| DCF (EBITDA 5y) | 9.69 - 12.97 | 11.49 | 77.4% |
| DCF (EBITDA 10y) | 9.41 - 13.53 | 11.52 | 77.7% |
| Fair Value | 0.58 - 0.58 | 0.58 | -90.98% |
| P/E | 3.18 - 4.34 | 3.95 | -39.1% |
| EV/EBITDA | 4.41 - 5.84 | 5.10 | -21.3% |
| EPV | 2.26 - 2.71 | 2.49 | -61.6% |
| DDM - Stable | 0.85 - 2.16 | 1.50 | -76.8% |
| DDM - Multi | 2.48 - 4.56 | 3.18 | -50.9% |
| Market Cap (mil) | 3,460.77 |
| Beta | 1.18 |
| Outstanding shares (mil) | 534.07 |
| Enterprise Value (mil) | 2,971.31 |
| Market risk premium | 6.13% |
| Cost of Equity | 9.27% |
| Cost of Debt | 5.00% |
| WACC | 8.58% |